Loading…
Attending this event?
For more information visit the symposium website: https://slas.org/events/slas-2020-european-sample-management-symposium
Tuesday, March 17 • 2:10pm - 2:30pm
Robots - Trends in Screening Tactics Deployed for Hit Identification and Implications for Sample Management

Sign up or log in to save this to your schedule and see who's attending!

Increasing success rates and decreasing cycle times are key objectives in the pharmaceutical industry. As such, screening platforms deployed to identify starting points for chemistry are constantly evolving to meet this challenge. Traditionally, Ultra High Throughput Screening of millions of compounds in 1536 well plates, and the sample management infrastructure which accompanies that, have been the cornerstone of hit identification in pharma, and have been used to successfully identify quality starting points for numerous projects. In the past decade, other technologies such as DNA Encoded Library Screening and Affinity Selection Mass Spectrometry have emerged, which reduce the requirement for extensive assay development and enable rapid identification of binders to the target of interest, often for multiple targets in parallel. Additionally, there has been an increase in the use of human disease relevant cell systems in early discovery with the aim of identifying molecules with improved clinical translation. However, the costs, the complexity of biology, and especially the limited scalability of cells, limit how these can be used at a scale compatible with high-throughput plate-based HTS formats.         Here we will discuss how the screening platforms described above are being deployed at GSK, and the interplay between those screening platforms and the sample management infrastructure that they critically depend on. We will discuss the challenges, and opportunities for sample management in the context of this evolving screening landscape.

Speakers
ML

Melanie Leveridge, BSc. hons

Director Screening and Sample Management, GlaxoSmithKline
Melanie is the Director of Screening Profiling and Mechanistic Biology at GSK, based in Stevenage, UK and has recently also taken accountability for the global small molecule Sample Management teams in the UK and US. Melanie has been with GSK since 2005 and in this time has held roles... Read More →

Chairs

Tuesday March 17, 2020 2:10pm - 2:30pm
Room Saphir